Selective protein enrichment in calcium oxalate stone matrix: a window to pathogenesis?


Journal

Urolithiasis
ISSN: 2194-7236
Titre abrégé: Urolithiasis
Pays: Germany
ID NLM: 101602699

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 01 10 2018
accepted: 28 03 2019
pubmed: 18 4 2019
medline: 26 3 2020
entrez: 18 4 2019
Statut: ppublish

Résumé

Urine proteins are thought to control calcium oxalate stone formation, but over 1000 proteins have been reported in stone matrix obscuring their relative importance. Proteins critical to stone formation should be present at increased relative abundance in stone matrix compared to urine, so quantitative protein distribution data were obtained for stone matrix compared to prior urine proteome data. Matrix proteins were isolated from eight stones (> 90% calcium oxalate content) by crystal dissolution and further purified by ultradiafiltration (> 10 kDa membrane). Proteomic analyses were performed using label-free spectral counting tandem mass spectrometry, followed by stringent filtering. The average matrix proteome was compared to the average urine proteome observed in random urine samples from 25 calcium oxalate stone formers reported previously. Five proteins were prominently enriched in matrix, accounting for a mass fraction of > 30% of matrix protein, but only 3% of urine protein. Many highly abundant urinary proteins, like albumin and uromodulin, were present in matrix at reduced relative abundance compared to urine, likely indicating non-selective inclusion in matrix. Furthermore, grouping proteins by isoelectric point demonstrated that the stone matrix proteome was highly enriched in both strongly anionic (i.e., osteopontin) and strongly cationic (i.e., histone) proteins, most of which are normally found in intracellular or nuclear compartments. The fact that highly anionic and highly cationic proteins aggregate at low concentrations and these aggregates can induce crystal aggregation suggests that protein aggregation may facilitate calcium oxalate stone formation, while cell injury processes are implicated by the presence of many intracellular proteins.

Identifiants

pubmed: 30993355
doi: 10.1007/s00240-019-01131-3
pii: 10.1007/s00240-019-01131-3
pmc: PMC8496971
mid: NIHMS1742352
doi:

Substances chimiques

Proteome 0
Calcium Oxalate 2612HC57YE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

521-532

Subventions

Organisme : CSRD VA
ID : I01 CX001491
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK082550
Pays : United States
Organisme : National Institues of Health/NIDDK
ID : DK 82550

Références

Proteomics. 2011 Mar;11(6):1058-63
pubmed: 21365761
Anal Sci. 2015;31(9):935-42
pubmed: 26353961
Urol Res. 2011 Aug;39(4):269-82
pubmed: 21229239
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):426-30
pubmed: 1729712
Clin Chim Acta. 2009 Oct;408(1-2):34-8
pubmed: 19595683
Scan Electron Microsc. 1983;(Pt 1):379-85
pubmed: 6635558
Biomed Res Int. 2013;2013:292953
pubmed: 24151593
J Proteome Res. 2009 Jun;8(6):3148-53
pubmed: 19358578
J Urol. 1956 Sep;76(3):213-27
pubmed: 13368269
Proteome Sci. 2016 Feb 27;14:4
pubmed: 26924944
Am J Physiol Renal Physiol. 2008 Oct;295(4):F1254-8
pubmed: 18701630
Proc Natl Acad Sci U S A. 2005 Jan 11;102(2):267-72
pubmed: 15625112
Proteome Sci. 2007 Sep 24;5:17
pubmed: 17892558
Clin Chim Acta. 1986 Jan 15;154(1):59-67
pubmed: 3943225
Clin Chim Acta. 1973 Jan 10;43(1):31-7
pubmed: 4351092
Urolithiasis. 2017 Feb;45(1):57-74
pubmed: 27913854
J Bone Miner Res. 1995 Dec;10(12):1913-29
pubmed: 8619372
J Clin Lab Anal. 2008;22(1):77-85
pubmed: 18200570
Clin Chim Acta. 2014 Feb 15;429:81-9
pubmed: 24333391
Urolithiasis. 2017 Aug;45(4):337-346
pubmed: 28314883
Urol Res. 2005 Jun;33(3):206-12
pubmed: 15864572
Calcif Tissue Int. 1989 Aug;45(2):122-8
pubmed: 2476205
Am J Physiol Renal Physiol. 2006 Dec;291(6):F1123-31
pubmed: 17082348
PLoS One. 2013 Jul 09;8(7):e68624
pubmed: 23874695
Urology. 2010 Oct;76(4):1017.e13-20
pubmed: 20709378
Int J Urol. 2012 Aug;19(8):765-72
pubmed: 22494008
Genome Biol. 2006;7(9):R80
pubmed: 16948836

Auteurs

Jeffrey A Wesson (JA)

Consultant Care Division/Nephrology Section, Department of Veterans Affairs Medical Center, Clement J Zablocki VA Medical Center, 5000 W National Avenue (111K), Milwaukee, WI, 53295, USA. jwesson@mcw.edu.
Department of Medicine/Division of Nephrology, Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, WI, 53226, USA. jwesson@mcw.edu.

Ann M Kolbach-Mandel (AM)

Department of Medicine/Division of Nephrology, Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, WI, 53226, USA.

Brian R Hoffmann (BR)

Department of Biomedical Engineering, Max McGee National Research Center, Cardiovascular Center, Medical College of Wisconsin and Marquette University, 9200 W Wisconsin Avenue, Milwaukee, WI, 53226, USA.
Department of Physiology, Max McGee National Research Center, Cardiovascular Center, Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, WI, 53226, USA.

Carley Davis (C)

Department of Urology, Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, USA.

Neil S Mandel (NS)

Department of Medicine/Division of Nephrology, Medical College of Wisconsin, 9200 W Wisconsin Avenue, Milwaukee, WI, 53226, USA.
Emeritus Professor, MCW, Milwaukee, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH